PSTV

Plus Therapeutics Inc

PSTV, USA

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

https://plustherapeutics.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PSTV
stock
PSTV

Investors get Plus Therapeutics business update in Jan. 22 webcast Stock Titan

Read more →
PSTV
stock
PSTV

Merger Talk: Should you avoid PSTV stock right now - 2025 Price Targets & Low Drawdown Momentum Ideas baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$7.1575

Analyst Picks

Strong Buy

1

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

99.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-87.51 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-23.69 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-184.32 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.69

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.59% of the total shares of Plus Therapeutics Inc

1.

Jane Street Group LLC

(0.1183%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0942%)

since

2025/07/31

3.

UBS Group AG

(0.0883%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.0843%)

since

2025/07/31

5.

Geode Capital Management, LLC

(0.0516%)

since

2025/06/30

6.

Vanguard Group Inc

(0.0328%)

since

2025/06/30

7.

Goldman Sachs Group Inc

(0.027%)

since

2025/06/30

8.

Millennium Management LLC

(0.0244%)

since

2025/06/30

9.

Ground Swell Capital, LLC

(0.0115%)

since

2025/06/30

10.

Cubist Systematic Strategies, LLC

(0.0103%)

since

2025/06/30

11.

Spartan Total Market Index Pool G

(0.0088%)

since

2025/07/31

12.

Fidelity Series Total Market Index

(0.0083%)

since

2025/07/31

13.

BlackRock Inc

(0.007%)

since

2025/06/30

14.

Tower Research Capital LLC

(0.0061%)

since

2025/06/30

15.

Fidelity Total Market Index

(0.0054%)

since

2025/07/31

16.

SBI Securities Co Ltd

(0.0023%)

since

2025/06/30

17.

NT Ext Equity Mkt Idx Fd - L

(0.0023%)

since

2025/06/30

18.

Northern Trust Extended Eq Market Idx

(0.0023%)

since

2025/06/30

19.

NT Ext Equity Mkt Idx Fd - NL

(0.0015%)

since

2025/06/30

20.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0011%)

since

2025/06/30

21.

State St US Extended Mkt Indx NL Cl C

(0.0007%)

since

2025/08/31

22.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0007%)

since

2025/06/30

23.

Spartan Extended Market Index Pool F

(0.0006%)

since

2025/07/31

24.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0006%)

since

2024/12/31

25.

Atlantic Union Bankshares Corp

(0.0005%)

since

2025/06/30

26.

Wells Fargo & Co

(0.0004%)

since

2025/06/30

27.

SSgA U.S. Total Market Index Strategy

(0.0003%)

since

2025/03/31

28.

Tradewinds Capital Management, LLC

(0.0002%)

since

2025/06/30

29.

Bank of America Corp

(0.0002%)

since

2025/06/30

30.

Advisor Group Holdings, Inc.

(0.0001%)

since

2025/06/30

31.

Northern Trust Wilshire 5000

(0.0001%)

since

2025/06/30

32.

JONES FINANCIAL COMPANIES LLLP

(0%)

since

2025/06/30

34.

AIGH Capital Management, LLC

(0%)

since

2025/03/31

35.

Barclays PLC

(0%)

since

2025/06/30

36.

Extended Equity Market Fund K

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.04

EPS Estimate

-0.7

EPS Difference

0.66

Surprise Percent

94.2857%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(3.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.